|
|
News Breaks | | | | November 19, 2012 | | 10:52 EDT |  | AMRN, GSK | Fish oil market may be bigger challenge than patents for Amarin, Forbes says
Scientific publications, doctors' commentary, and prescription trends all hint that the U.S. market for prescription fish oil may be shifting dramatically, which could be a bigger problem for Amarin (AMRN) than patent protection for its Vascepa drug, according to Forbes. Use of GlaxoSmithKline's (GSK)Lovaza, an alternative treatment, has declined, the report added. Reference Link | |
|
News For AMRN;GSK From The Last 14 Days Check below for free stories on AMRN;GSK the last two weeks. |
|
|
| There are no results for AMRN;GSK |
|
|
|
|
|
|
